Martec/Egis Pharmaceuticals partnership
Martec agreement with Budapest, Hungary-based firm provides the U.S. company with all pharmaceutical compounds developed by Egis over the next 13 years. Martec will have the exclusive right to market these compounds in the U.S., Canada and Mexico. Martec also will aid Egis in establishing a new R&D facility. Egis generates annual revenues of $ 175 mil., according to Martec.
You may also be interested in...
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.
IBA’s name change refines its identity as the representative of the independent and entrepreneurial beauty industry, according to the trade organization’s announcement. The group’s FDA Cosmetics Regulation Workshop, held annually since 1983 in cooperation with the FDA, will be virtual in 2020.
Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.